<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161304</url>
  </required_header>
  <id_info>
    <org_study_id>T-001</org_study_id>
    <nct_id>NCT00161304</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency</brief_title>
  <official_title>Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leonard S. Marks, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Watson Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urological Sciences Research Foundation</source>
  <brief_summary>
    <textblock>
      The T-001 study is a placebo-controlled investigation of the effects of injectable&#xD;
      testosterone replacement therapy on prostate tissues of aging men with low testosterone&#xD;
      levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The T-001 study is a placebo-controlled investigation of the effects of injectable&#xD;
      testosterone replacement therapy on prostate tissues of aging men with low testosterone&#xD;
      levels. The primary objectives of the study are to measure the changes in tissue hormones and&#xD;
      other biomarkers in the prostate tissue specimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2003</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Men With Low Testosterone Levels</condition>
  <arm_group>
    <arm_group_label>Testosterone Enanthate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate</intervention_name>
    <description>Testosterone Enanthate</description>
    <arm_group_label>Testosterone Enanthate</arm_group_label>
    <other_name>testosterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The screening evaluation consisted of:&#xD;
&#xD;
          1. medical history, which included the androgen deficiency of the aging male&#xD;
             questionnaire&#xD;
&#xD;
          2. physical examination&#xD;
&#xD;
          3. multiphasic serum panel&#xD;
&#xD;
          4. measurement of total serum testosterone and PSA levels&#xD;
&#xD;
        Exclusion criteria included:&#xD;
&#xD;
          1. use in the past 6 months of any drug potentially affecting the pituitary-gonadal axis&#xD;
&#xD;
          2. serum PSA level greater than 10.0 ng/mL&#xD;
&#xD;
          3. refusal or inability to undergo prostate biopsies&#xD;
&#xD;
          4. presence of prostate cancer on initial biopsy results.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard S Marks, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urological Sciences Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Sciences Research Foundation</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.usrf.org</url>
    <description>Urological Sciences Research Foundation</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Urological Sciences Research Foundation</investigator_affiliation>
    <investigator_full_name>Leonard S. Marks, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

